manufacturing_capacity

BROOMFIELD – October 22, 2026 -- BAE Systems (LON: BA) has closed on the purchase of a 130,000-square-foot production facility in Weld County, Colorado, and expects to hire more than 200 people there over the next 12 to 24 months.

The building sits on about 13 acres. BAE Systems will use it to expand manufacturing capacity for space-based hardware and sensor systems, citing customer demand and business growth.

BAE Systems targets 600 jobs at full capacity

The company estimates the site could employ approximately 600 people at full capacity. The initial hiring wave of more than 200 positions will support production ramp-up.

Retrofit starts this year, production slated for early 2028

BAE Systems plans to begin retrofitting the facility and procuring equipment through the rest of this year. It anticipates opening the site for production in early 2028.

Tucson – October 19, 2026 -- The U.S. Army has awarded the Javelin Joint Venture (JJV), a partnership between Raytheon, an RTX business, and Lockheed Martin, a $215 million production contract for the Lightweight Command Launch Unit (LWCLU), the next-generation launcher for the Javelin weapon system.

The LWCLU replaces the legacy command launch unit. The award follows by five months the JJV's delivery of the first LWCLUs to the Army.

New launcher is 30% smaller and 25% lighter than the Block I unit

Compared with the current Block I Command Launch Unit, the LWCLU is 30% smaller and 25% lighter. It also doubles target detection and recognition. The unit is built to give soldiers maximum surveillance and offers day and night engagement capability.

The launcher is designed to be compatible with all current, past and future Javelin variants.

Singapore – September 21, 2026 -- WuXi XDC Cayman Inc. (2268.HK) has secured GMP release for its Singapore manufacturing site at Tuas Biomedical Park, marking the bioconjugate CRDMO's first overseas facility just two and a half years after the site was announced in March 2024.

BCM3 dual-function line and DP4 drug product facility clear GMP release

The 25,000-square-meter site achieved GMP release for both its BCM3 antibody intermediate and conjugated drug substance production line and its DP4 drug product facility in August 2026. BCM3 supports batch sizes from 200 L to 2,000 L for antibody intermediates and up to 2,000 L for conjugated drug substances, operating under FDA, EMA and NMPA standards. A second line, BCM4, is slated for GMP release by the end of 2026 with a maximum single-batch capacity of 500 L for conjugated drug substance.

Seoul – September 14, 2026 -- DB HiTek has completed reliability qualification for its 1,200V silicon carbide (SiC) MOSFET manufacturing process on 8-inch (200mm) wafers, establishing what the company calls the world's first complete 8-inch SiC foundry process. Mass production is scheduled for 2027.

DB HiTek builds the industry's first full-scale 8-inch SiC foundry pipeline

The South Korean foundry, which specializes exclusively in 8-inch wafer production, has set up an end-to-end service covering design, fabrication, electrical characterization, and reliability qualification for high-power SiC MOSFETs. Most SiC production today runs on 6-inch wafers, but major chipmakers are shifting toward 8-inch substrates to cut per-unit costs and boost manufacturing efficiency, a transition DB HiTek is positioning itself to capture early.

Hamilton, Ontario – – September 10, 2026 -- AtomVie Global Radiopharma has officially opened a new manufacturing plant at 10 Aeropark Boulevard in Hamilton, Ontario, representing an investment exceeding $160 million and marking the largest contract development and manufacturing organization (CDMO) site in North America dedicated to radiopharmaceutical production.

Facility spans 6,700 square meters and multiplies output tenfold

The site covers more than 6,700 square meters and increases AtomVie's production capacity by more than tenfold, supporting variable low-to-high throughput manufacturing. Modular spaces are designed to allow a smooth transition from early-stage clinical development to full commercial-scale production of radiopharmaceuticals.